CGON News and Press, CG Oncology, Inc.

CG Oncology, Inc. (CGON) is expected to report $-0.61 for Q4 2025

2026-02-27 14:13:41 ET More on CG Oncology CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript CG Oncology: 'Strong Buy' On Earlie...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026 Well-posit...

IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March...

2026-02-19 17:15:50 ET Connecticut-based Braidwell reported selling 1,412,746 shares of CG Oncology (NASDAQ:CGON) in its February 17, 2026, SEC filing, an estimated $58.46 million trade based on quarterly average pricing. According to a February 17, 2026, SEC filing , Braidwell ...

2026-01-16 07:05:20 ET Kelsey Goodwin from Piper Sandler issued a price target of $70.00 for CGON on 2026-01-16 11:55:13. The adjusted price target was set to $70.00. At the time of the announcement, CGON was trading at $53.07. The overall price target consensus is at $7...

2026-01-15 15:15:57 ET CG Oncology, Inc. (CGON) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 11:15 AM EST... Read the full article on Seeking Alpha For further details see: CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference T...

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Str...

Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Jan. 12, 2026 /CNW/ -- USANewsGroup .com   News Commentary – The oncology landscape is en...

2026-01-11 08:30:11 ET The last time I spoke about CG Oncology ( CGON ) it was with respect to a Seeking Alpha article entitled " CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene ". With respect to this article, I noted that the company had achieved ...